FXR nucl. receptor + TGR5 GPCR dual agonist

dual in vivo effects at 100 mpk PO

from merger of literature agonist fragments

Sci. Rep., Apr. 28, 2021

Fuji Yakuhin Co., Ltd., Saitama, JP

The Fuji Yakuhin FXR/TGR5 non-bile acid dual agonist, compound 20p, simultaneously activates the FXR nuclear receptor and the unrelated TGR5 GPCR receptor when dosed orally in vivo. FXR has been…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.